Department of Infectious Diseases Epidemiology and Modeling, Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Department of Microbiology, Oslo University Hospital, Oslo, Norway.
PLoS One. 2019 Aug 13;14(8):e0221084. doi: 10.1371/journal.pone.0221084. eCollection 2019.
Infection with varicella zoster virus (VZV) in pregnancy may lead to serious outcomes both for the mother and the newborn. Targeted screening and vaccination of non-immune women during reproductive age could prevent varicella infection in pregnancy. Currently, no universal varicella screening of pregnant women is implemented in Norway, but serological testing in pregnancy is recommended in particular situations. We examined seroprevalence of VZV in a national pregnancy cohort in order to help assess a need for VZV screening of women during reproductive age.
We determined the susceptibility to VZV and the reliability of self-reported history of VZV infection in the Norwegian obstetric population by using a random sample of 1,184 pregnant women from the Norwegian Mother and Child Cohort study (MoBa). The MoBa study included approximately 95,200 pregnant women in Norway between 1998 and 2009. Blood samples taken at gestational week 17-18 were analysed using a commercial enzyme immunoassay for specific IgG antibodies to Varicella-Zoster virus. Second sample taken at birth was tested if the first sample result was negative or equivocal.
Of the 1,184 pregnant women, 98.6% (n = 1,167) were seropositive, 0.83% (n = 10) remained seronegative, and four women (0.34%) seroconverted during their pregnancy. No significant associations were found between serological status and women's age at birth, gestational age, women's country of birth and year of child's birth. One woman reported prior history of varicella, whereas 143 (12.1%) women reported a household exposure to childhood diseases with fever and rash, of which 25 reported exposure to varicella, of which all were seropositive.
The findings support antenatal screening recommendations in Norway advising testing for VZV in pregnant women with unknown immunity to VZV. Further studies are however needed to better identify target groups for screening and vaccination.
妊娠期间感染水痘带状疱疹病毒(VZV)可能会对母亲和新生儿造成严重后果。对育龄期非免疫女性进行针对性筛查和疫苗接种可以预防妊娠期间水痘感染。目前,挪威没有对孕妇进行普遍的水痘筛查,但建议在特殊情况下对孕妇进行血清学检测。我们对挪威全国妊娠队列进行了 VZV 血清流行率检测,以帮助评估育龄期妇女进行 VZV 筛查的必要性。
我们使用挪威母婴队列研究(MoBa)中的 1184 名随机抽取的孕妇的样本,通过检测 VZV 易感性和自我报告 VZV 感染史的可靠性,来确定挪威产科人群中的 VZV 易感性和自我报告 VZV 感染史的可靠性。MoBa 研究在 1998 年至 2009 年间纳入了大约 95200 名挪威孕妇。在妊娠 17-18 周时采集血样,采用商业酶联免疫吸附试验检测特异性 IgG 抗体。如果第一次样本检测结果为阴性或不确定,则在分娩时采集第二次样本进行检测。
在 1184 名孕妇中,98.6%(n=1167)为血清阳性,0.83%(n=10)仍为血清阴性,4 名孕妇(0.34%)在妊娠期间发生血清转化。血清学状态与孕妇的出生年龄、妊娠周数、孕妇的出生国和儿童的出生年份之间没有显著关联。一名孕妇报告了先前的水痘病史,143 名(12.1%)女性报告了有发热和皮疹的儿童疾病的家庭接触史,其中 25 名报告了接触水痘,均为血清阳性。
这些发现支持挪威的产前筛查建议,建议对 VZV 免疫力未知的孕妇进行 VZV 检测。然而,需要进一步研究以更好地确定筛查和疫苗接种的目标人群。